Matrix metalloproteinase-9 expression in alveolar extraction sockets of zoledronic acid-treated rats

Journal of Oral and Maxillofacial Surgery

Volumn 69, Issue 11, 2011, Pages 2698-2707

  Basi, David L ^a   Hughes, Pamela J ^a   Thumbigere Math, Vivek ^a   Sabino, Ma'Ann ^a   Mariash, Ami ^a   Lunos, Scott A ^b   Jensen, Eric ^a   Gopalakrishnan, Rajaram ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; SODIUM CHLORIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ZOLEDRONIC ACID;

ALVEOLAR BONE; ANIMAL EXPERIMENT; ARTICLE; BONE MINERALIZATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TOOTH EXTRACTION; TOOTH SOCKET; WESTERN BLOTTING; WOUND HEALING; ZYMOGRAPHY;

ALVEOLAR PROCESS; ANIMALS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHONATES; FLUORESCENT DYES; IMIDAZOLES; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MAXILLA; MOLAR; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TOOTH EXTRACTION; TOOTH SOCKET; WOUND HEALING;

EID: 80054960230     PISSN: 02782391     EISSN: 15315053     Source Type: Journal    
DOI: 10.1016/j.joms.2011.02.065     Document Type: Article

References (46)

1. J.R. Berenson Advances in the biology and treatment of myeloma bone disease Am J Health Syst Pharm 58 Suppl 3 2001 S16
2. T. Kylmala, T.L. Tammela, and T.S. Lindholm The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer Ann Chir Gynaecol 83 1994 316
3. A. Lipton, E. Small, and F. Saad The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate Cancer Invest 20 Suppl 2 2002 45
4. G. Carteni, R. Bordonaro, and F. Giotta Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: A multicenter clinical trial Oncologist 11 2006 841
5. F. Saad, J. McKiernan, and J. Eastham Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis Urol Oncol 24 2006 4
6. R.E. Marx Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic J Oral Maxillofac Surg 61 2003 1115
7. S.L. Ruggiero, B. Mehrotra, and T.J. Rosenberg Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases J Oral Maxillofac Surg 62 2004 527
8. J.F. Bukowski, C.C. Dascher, and H. Das Alternative bisphosphonate targets and mechanisms of action Biochem Biophys Res Commun 328 2005 746
9. J.R. Green Bisphosphonates: Preclinical review Oncologist 9 Suppl 4 2004 3
10. G.A. Rodan Mechanisms of action of bisphosphonates Annu Rev Pharmacol Toxicol 38 1998 375
11. G.A. Rodan, and T.J. Martin Therapeutic approaches to bone diseases Science 289 2000 1508
12. B. Steffensen, L. Hakkinen, and H. Larjava Proteolytic events of wound-healingCoordinated interactions among matrix metalloproteinases (MMPs), integrins, and extracellular matrix molecules Crit Rev Oral Biol Med 12 2001 373
13. J.M. Ray, and W.G. Stetler-Stevenson Gelatinase A activity directly modulates melanoma cell adhesion and spreading EMBO J 14 1995 908
14. T. Salo, M. Makela, and M. Kylmaniemi Expression of matrix metalloproteinase-2 and -9 during early human wound healing Lab Invest 70 1994 176
15. G.P. Stricklin, L. Li, and V. Jancic Localization of mRNAs representing collagenase and TIMP in sections of healing human burn wounds Am J Pathol 143 1993 1657
16. H. Nagase Matrix metalloproteinases A mini-review Contrib Nephrol 107 1994 85
17. P. Chen, and W.C. Parks Role of matrix metalloproteinases in epithelial migration J Cell Biochem 108 2009 1233
18. C.I. Colnot, and J.A. Helms A molecular analysis of matrix remodeling and angiogenesis during long bone development Mech Dev 100 2001 245
19. D.G. Armstrong, and E.B. Jude The role of matrix metalloproteinases in wound healing J Am Podiatr Med Assoc 92 2002 12
20. C. Colnot, Z. Thompson, and T. Miclau Altered fracture repair in the absence of MMP9 Development 130 2003 4123
21. T.H. Vu, J.M. Shipley, and G. Bergers MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes Cell 93 1998 411
22. M.T. Engsig, Q.J. Chen, and T.H. Vu Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones J Cell Biol 151 2000 879
23. O. Ishibashi, S. Niwa, and K. Kadoyama MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration Life Sci 79 2006 1657
24. H. Valleala, R. Hanemaaijer, and J. Mandelin Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates Life Sci 73 2003 2413
25. E. Giraudo, M. Inoue, and D. Hanahan An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J Clin Invest 114 2004 623
26. A.O. Hoff, B.B. Toth, and K. Altundag Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 2008 826
27. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta Delta c(T)) method Methods 25 2001 402
28. A.R. Quesada, M.M. Barbacid, and E. Mira Evaluation of fluorometric and zymographic methods as activity assays for stromelysins and gelatinases Clin Exp Metastasis 15 1997 26
29. K. Donath, and G. Breuner A method for the study of undecalcified bones and teeth with attached soft tissues The Sage-Schliff (sawing and grinding) technique J Oral Pathol 11 1982 318
30. M.D. Rohrer, and C.C. Schubert The cutting-grinding technique for histologic preparation of undecalcified bone and bone-anchored implants Improvements in instrumentation and procedures Oral Surg Oral Med Oral Pathol 74 1992 73
31. L. Blavier, and J.M. Delaisse Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones J Cell Sci 108 1995 3649
32. D.P. Rice, H.J. Kim, and I. Thesleff Detection of gelatinase B expression reveals osteoclastic bone resorption as a feature of early calvarial bone development Bone 21 1997 479
33. N. Angelov, N. Moutsopoulos, and M.J. Jeong Aberrant mucosal wound repair in the absence of secretory leukocyte protease inhibitor Thromb Haemost 92 2004 288
34. K. Sundaram, R. Nishimura, and J. Senn RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation Exp Cell Res 313 2007 168
35. J. Li, I. Sarosi, and X.Q. Yan RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism Proc Natl Acad Sci USA 97 2000 1566
36. K. Fuller, C. Murphy, and B. Kirstein TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL Endocrinology 143 2002 1108
37. S.S. Huja, S.A. Fernandez, and C. Phillips Zoledronic acid decreases bone formation without causing osteocyte death in mice Arch Oral Biol 54 2009 851
38. K. Iwata, J. Li, and H. Follet Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia Bone 39 2006 1053
39. I.R. Orriss, M.L. Key, and K.W. Colston Inhibition of osteoblast function in vitro by aminobisphosphonates J Cell Biochem 106 2009 109
40. V. Lambert, B. Wielockx, and C. Munaut MMP-2 and MMP-9 synergize in promoting choroidal neovascularization FASEB J 17 2003 2290
41. T. Accorsi-Mendonca, K.B. Paiva, and W.F. Zambuzzi Expression of matrix metalloproteinases-2 and -9 and RECK during alveolar bone regeneration in rat J Mol Histol 39 2008 201
42. L. Liu, F.M. He, and L.L. Li [The expression of MMP-9, MMP-2 in the remodeling bone tissue around implant during unloaded period] Hua Xi Kou Qiang Yi Xue Za Zhi 22 2004 325
43. E. Roeb, I. Behrmann, and J. Grotzinger An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist FASEB J 14 2000 1671
44. H. Yasuda, N. Shima, and N. Nakagawa Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 1998 3597
45. R. Reyes-Garcia, M. Munoz-Torres, and D.F. Garcia Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis Menopause 17 2010 140
46. D. Stefanik, J. Sarin, and T. Lam Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate Oral Dis 14 2008 465